Alopecia Areata: Clinical Characteristics of Those With and Without Poliosis
Poliosis may be induced among elderly persons with AA who have a poor melanocyte reservoir status.
Poliosis may be induced among elderly persons with AA who have a poor melanocyte reservoir status.
Dupilumab, commonly used for eczema, may be effective for hair regrowth in patients with alopecia totalis and atopic dermatitis.
Complete or near-complete hair regrowth occurred in 5 patients, with a 98% improvement in the Severity of Alopecia Tool score.
Hair growth outcomes with contact immunotherapy for alopecia areata were associated with many factors and there was a significant variability in the criteria used.
Patients with alopecia areata may have multiple risk factors for mental health disorders, including psychological distress and impaired quality of life.
PF-06651600 is an investigational oral Janus kinase 3 (JAK3) inhibitor that is being evaluated in a Phase 2 study which will assess the treatment based on changes from baseline in Severity of Alopecia Tool (SALT) score.
Patients were most often affected by feelings of embarrassment and self-consciousness, followed by effects on social and leisure activities.
Carboxytherapy is a promising therapeutic treatment option for patchy alopecia areata and could be used as an adjuvant therapy of androgenetic alopecia.
The FDA has granted Fast Track designation for CTP-543, a novel oral Janus kinase inhibitor for the treatment of moderate-to-severe alopecia areata, which currently has no approved treatments.
Restricting the number of thyroid function screenings performed could reduce health care costs, standardize clinical practices, and eliminate unnecessary testing.